Revista de investigación y terapia de adicciones

Abstracto

Depression-an Open Label Comparative Study

Neelofar J* and Insha MK

While Naltrexone is a competitive receptor antagonist, buprenorphine is a partial mu-opioid agonist and kappa antagonist. By removing opioids from the receptors, the partial agonist activity of buprenorphine can induce withdrawal in opioid dependent patients. It is regulated sublingually, sublingual, Though Naltrexone has a more prominent partiality for μ receptors than heroin and other narcotic agonists. Utilizing buprenorphine and naltrexone for treatment aims to reduce illicit opioid use and increase treatment retention. Naltrexone and buprenorphine maintenance treatment has been started in opiate-dependent people, and the goal of our study was to see if there was a link between depression and the medication.
At 2, 4, and 6 weeks, the Naltrexone group's depressive mood was significantly higher than the Buprenorphine group's. The Naltrexone group had significantly more insomnia, psychiatric and somatic anxiety, hypochondriasis,and gastrointestinal symptoms than the Buprenorphine group did. It was discovered that buprenorphine has an antidepressant effect.
We concluded from our research that Buprenorphine was associated with higher HAM-D scores and Naltrexone was associated with depression.